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A B S T R A C T
Objectives: Investigation of the blood compatibility requires a number of sensitive assays to quantify the acti-
vation of the blood protein cascades and cells induced by biomaterials. A global assay measuring the blood
compatibility of biomaterials could be a valuable tool in such regard. In this study, we investigated whether an
enzyme-linked immunosorbent assay (ELISA), that speciﬁcally measures the electrophoretic “fast form” of α2-
macroglobulin (F-α2M), could be a sensitive and global marker for activation of calcium dependent and in-
dependent proteases in plasma exposed to biomaterials in vitro.
Methods: A F-α2M speciﬁc monoclonal antibody was generated and applied in an ELISA setup. Using the F-α2M
ELISA, we investigated activation of calcium dependent and in-dependent proteases by polyvinylchloride
(n = 10), polytetraﬂuoroethylene (n = 10) and silicone (n = 10) tubings as well as glass tubes (n = 10).
Results: We found that F-α2M is a sensitive marker for activation of both calcium dependent and in-dependent
proteases. A signiﬁcant diﬀerence between F-α2M concentrations in the control sample and plasma exposed to
the artiﬁcial surfaces was found (p > 0.001). This was observed both in the presence and absence of calcium.
Furthermore, the highest F-α2M concentration was in both cases found in plasma incubated with glass.
Conclusions: Our ﬁndings demonstrate that F-α2M is a sensitive marker for detection of protease activation in
plasma by artiﬁcial surfaces. Potentially, levels of F-α2M could be a global marker of the blood compatibility of
biomaterials.
1. Introduction
Exposure of human blood to artiﬁcial surfaces in clinical settings is
frequently associated with an increased risk of thrombotic and in-
ﬂammatory reactions [1–3]. These complications arise from a complex
inter-play between surface induced protein adsorption, cell adhesion,
and a series of blood protein cascades: the contact system, coagulation,
and the complement system [4]. Protein adsorption of contact factors to
artiﬁcial devices or the action of tissue factor from blood cells has been
suggested to be initiators of coagulation [2,5,6]. Activation of the
complement system induced by artiﬁcial surfaces is reportedly medi-
ated through the alternative and classical pathways [7,8] and the
contact system [4]. Currently, the use of biomaterials in clinical settings
require administration of anticoagulants to minimize thrombotic com-
plications. Such an approach, however, does not completely prevent the
complications triggered by interaction of blood with artiﬁcial surfaces
[2,4]. Furthermore, studies investigating inhibition of the complement
cascade or the contact activation system, as a new approach to improve
the blood compatibility of biomaterials, highlight the complexity of the
interaction between blood and artiﬁcial surfaces [2,4]. Investigations of
the blood compatibility and development of new biomaterials therefore
call for the use of several assays measuring initiation of the contact
system, coagulation, and the complement cascade as well as markers for
platelet and leukocyte activation. The International Standardization
Organization (ISO) 10993-4 standard describes a number of assays to
study speciﬁc analytes that reveal the activation status of these biolo-
gical systems. However, no global and sensitive immunoassay exists for
detection of activation of proteases induced by biomaterials. Such assay
could be useful in search of biomaterials with improved blood com-
patibility.
The broad-spectrum inhibitor, α2-macroglobulin (α2M), interacts
with a vast number of proteinases in blood including those involved in
contact activation and coagulation [9]. In human blood, α2M circulates
as a 725 kDa tetramer in a concentration of about 2.4 mg/mL [10].
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Upon interaction with a proteinase, α2M undergoes an irreversible
conformational change into a complexed or electrophoretic “fast form”
(F-α2M) [11] and exposes an otherwise hidden receptor-binding-do-
main (RBD) [12–14]. Based on this, we hypothesized that detection of
F-α2M could be sensitive and global approach for evaluation of the
blood compatibility of biomaterials; an increase in F-α2M levels would
indicate activation of proenzymes from one or more enzymatic cas-
cades.
In this study, we generated a F-α2M speciﬁc antibody and applied
this in an enzyme-linked immunosorbent assay (ELISA) setup to mea-
sure F-α2M in plasma. Furthermore, we investigated whether the F-α2M
ELISA could detect activation of calcium dependent and in-dependent
proteases in plasma after incubation with artiﬁcial surfaces.
2. Materials and methods
2.1. Buﬀers
Coating buﬀer (15 mM Na2CO3, 35 mM NaHCO3, pH = 9.6). PBS-
TW buﬀer (PBS, 0.05% Tween-20, pH = 7.4). Substrate buﬀer (25 mM
citric acid, 97 mM Na2HPO4, pH = 5.0). Sample dilution buﬀer (PBS-
TW, 10 mM EDTA, 33.3 μM Phe-Pro-Arg-chloromethylketone (PPACK),
pH = 7.4). TBS buﬀer (50 mM Tris-HCl, 150 mM NaCl, pH = 7.4 (at
37 °C)).
2.2. Plasma
A sodium citrate (0.109 M) stabilized plasma pool was obtained in-
house from 20 healthy individuals (9 males, 11 females) who did not
take hormone supplements. A serum pool was obtained from 22 healthy
individuals (12 males, 10 females). Plasma and serum were stored at
−80 °C in 250 μL ampoules.
2.3. Reagents
Ortho-phenylenediamine (OPD) tablets were from Sigma-Aldrich
Denmark ApS (Brøndby, Denmark). 3,3′,5,5′-tetramethylbenzidine
(TMB) One™ ready-to-use substrate was from Kem-en-Tec Diagnostics
A/S (Taastrup, Denmark). 30% H2O2 solution was from Merck
(Darmstadt, Germany). 96-well polystyrene ﬂat bottom MicroWell™
Maxisorp™ plates (Maxisorp plates) were from Thermo Fisher Scientiﬁc
(Roskilde, Denmark). Methylamine (MA) was from Sigma.
Human native α2M (N-α2M) and human F-α2M were from Sigma.
Polyclonal goat anti-human α2M IgG antibody (Cat. No. GAA2M-AP)
was from Aﬃnity Biologicals (Ancaster, Ontario, Canada). The antibody
was dialyzed against PBS and subsequently biotinylated with N-hy-
droxydsuccinimide activated biotin (1 mg/6 mg antibody) for 3 h at RT.
Finally, the antibody was dialyzed against PBS (biotinylated α2M an-
tibody). Horseradish peroxidase (HRP) conjugated streptavidin (HRP-
Strp) was from Thermo Fisher Scientiﬁc. HRP conjugated rabbit anti-
mouse IgG antibody (Cat. No. A9044) was from Sigma. Procoagulant
phospholipid-TGT (TGT-lipid) was from Sweden). PPACK was from
Haematologic Technologies Inc. (Essex Junction, Vermont, USA).
Recombinant RBD (rRBD) of human α2M, cloned in vector pQE-30
with E. coli as expression system, was from Genscript (Piscataway, New
Jersey, USA). The rRBD was expressed and puriﬁed as described else-
where [15].
HiTrap™ Protein G HP 5 mL column (Protein G column) was from
GE Healthcare Europe GmbH (GE Healthcare, Brøndby, Denmark).
MA-treated α2M was prepared by incubating 1 mg/mL N-α2M with
200 mM MA over-night (ON) at room temperature (RT). Subsequently,
the sample was dialyzed against TBS buﬀer.
VWR Collection Silicone (Cat. No. 228-0706), Thermo Scientiﬁc
Nalgene® polyvinylchloride (PVC) (Cat. No. 228-0178), and BOLA
polytetraﬂuoroethylene (PTFE) (Cat. No. 228-0745) tubings, with a
3 mm internal diameter, were from VWR – Bie & Berntsen A/S (Søborg,
Denmark). VWR Collection glass tubes, with a 10 mm external diameter
and a U-bottom shape, were obtained from VWR.
2.4. F-α2M speciﬁc monoclonal antibody
Mouse anti-human F-α2M monoclonal antibodies were produced
essentially as described previously [16]. Brieﬂy, NMRI mice were im-
munized subcutaneously, three times, with 25 μg MA-treated α2M ad-
sorbed to Al(OH)3 and mixed in a 1/1 ratio with Freund's incomplete
adjuvant. A last immunization of 25 μg antigen was administrated in-
travenously three days prior to fusion. Spleen cells were subsequently
fused with SP2/0-AG14 myeloma cells using polyenthylene glycol, and
the fused cells were cultured in enriched RMPI 1640 medium. To
identify hybridoma clones expressing F-α2M speciﬁc antibodies, the
culture supernatants of hybridoma cells were contra-screened using
Maxisorp plates coated with either 1 μg/mL N-α2M or F-α2M. Wells
with superior signal generation on F-α2M coated plates were identiﬁed,
and the hybridoma clones corresponding to these wells were cloned
using the limited dilution method. Once single clones were obtained,
the cells were grown in large scale and antibodies were puriﬁed from
culture supernatant using the Protein G column. The antibodies, 16-11-
2, 16-11-15, and 16-11-17, were selected for further studies to de-
monstrate speciﬁcity for F-α2M.
2.4.1. Demonstration of F-α2M speciﬁcity
Recognition of rRBD by 16-11-2, 16-11-15, and 16-11-17 was in-
vestigated by ELISA. Brieﬂy, a Maxisorp plate was coated with 4 μg/mL
rRBD or 1 μg/mL N-α2M and incubated ON at 4 °C. After a washing
step, 2 μg/mL of either 16-11-2, 16-11-15, 16-11-17, or mouse anti-
human tissue plasminogen activator (t-PA) antibody (nonsense anti-
body developed in-house), diluted in PBS-TW, were added to the wells
and the plate was incubated for 60 min at RT under agitation.
Following another washing step, HRP conjugated rabbit anti-mouse
IgG, diluted 1:4000 in PBS-TW, was added to the wells and the plate
was incubated for another 60 min at RT under agitation. Finally, the
plate was washed and color development was initiated by adding
100 μL of a solution containing 0.012% H2O2 and 0.6 mg/mL OPD in
substrate buﬀer. After 15 min, 100 μL 1 M H2SO4 was added to stop the
reaction. The color development was quantiﬁed by measuring the op-
tical density (OD) at 492 nm using OD readings at 650 nm as reference.
The electrophoretic mobility of F-α2M and N-α2M in presence of 16-
11-17 was investigated on native PAGE. Brieﬂy, 100 μg/mL of either F-
α2M or N-α2M was incubated in the presence of 40 μg/mL 16-11-17 or
buﬀer for 2 h at 4 °C in PBS. Subsequently, the samples were diluted 1:1
in 2× native sample buﬀer (62.5 mM Tris-HCl, 40% glycerol, 0.01%
Bromophenol Blue, pH = 6.8) (Bio-Rad) and analyzed by native PAGE
using a 4–15% MiniPROTEAN® TGX™ precast gel (Bio-Rad) with TG
running buﬀer (Bio-Rad), as described by the manufacturer, for 80 min
at 150 V. The proteins in the gel were then visualized using Bio-Safe™
Coomassie G-250 stain (Bio-Rad) as instructed by the manufacturer.
2.5. Assay development
During assay development, the following setup was used; Maxisorp
plates were coated with 1 μg/mL 16-11-17 by adding 100 μL of anti-
body solution in coating buﬀer to each well and incubating the plates
ON at 4 °C. The plates were washed three times with PBS-TW and
blocked for 40 min in PBS-TW buﬀer. Samples were diluted in PBS-TW
(with 10 mM EDTA) and 100 μL was added to the plates and incubated
for 60 min at RT under agitation. Following another washing step,
100 μL of diluted biotinylated α2M antibody (1:2000 in PBS-TW) was
added to the wells and the plates were incubated for 60 min at RT under
agitation. Next, the plates were washed 3 times with PBS-TW, and
100 μL HRP-Strp, diluted 1:4000 in PBS-TW, was added to each well.
The plates were incubated for 60 min at RT under agitation. Color de-
velopment was initiated by adding 100 μL of a solution containing
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0.012% H2O2 and 0.6 mg/mL OPD in substrate buﬀer. After 12 min,
100 μL 1 M H2SO4 was added to stop the reaction. The color develop-
ment was quantiﬁed by measuring the OD at 492 nm using OD readings
at 650 nm as reference. To calculate the concentration of F-α2M in the
samples tested, a 4-parameter nonlinear logistic (4-PL) curve was ﬁtted
to the OD measurement obtained from the calibrator wells. The ﬁt was
used to convert the measured OD values of the samples into F-α2M
concentrations. The calculated concentrations were multiplied by the
initial dilution factor.
2.5.1. Spike and recovery
The citrate plasma pool was spiked with 0, 1.0, or 1.5 μg/mL F-α2M.
The level of F-α2M in the plasma samples (diluted 1:100) were mea-
sured using the assay setup described in Section 2.5 and compared with
the theoretical increase. The experiment was conducted three times
with quadruple measurements. The recovery was calculated as a per-
centage of the mean values.
2.5.2. Parallelism
Parallelism between serial dilutions of the serum pool, F-α2M in
buﬀer (50 μg/mL), and the citrate plasma pool spiked with 50 μg/mL F-
α2M was studied. The samples were diluted 1:100 in sample dilution
buﬀer and further 2-fold diluted on the plate. The dilutions were ana-
lyzed in duplicates as described in Section 2.5. The obtained data were
then ﬁtted to a 4-PL curve.
2.5.3. Sample dilution buﬀer
The eﬀect of PPACK in the sample dilution buﬀer was studied. The
citrate plasma pool and the serum pool were diluted 1:100 or 1:4000,
respectively, and analyzed as described in Section 2.5 with the only
diﬀerence that the samples were diluted in PBS-TW (with 10 mM
EDTA) with or without 33.3 μM PPACK and incubated for 60, 120, or
180 min on the plates.
2.6. F-α2M ELISA
Maxisorp plates were coated with 2 μg/mL 16-11-17 by adding
100 μL of antibody solution in coating buﬀer to each well and in-
cubating the plates ON at 4 °C. The plates were then washed three times
with PBS-TW and the wells were blocked for 120 min in PBS-TW buﬀer.
Samples and calibrator were diluted in sample dilution buﬀer and
100 μL was added to the plates and incubated for 60 min at RT under
agitation. Following another washing step, 100 μL of diluted biotiny-
lated α2M antibody (1:500 in PBS-TW) was added to the wells and the
plates were incubated for 60 min at RT under agitation. The plates were
washed 3 times with PBS-TW and 100 μL HRP-Strp, diluted 1:3000 in
PBS-TW, was added to each well. The plates were incubated for 60 min
at RT under agitation. Color development was initiated by adding
100 μL of TMB One substrate solution to each well. After 9 min, 100 μL
of 0.2 M H2SO4 was added to each well to stop the reaction. The color
development was quantiﬁed by measuring the OD at 450 nm using OD
readings at 650 nm as reference. A 4-PL curve was ﬁtted to the OD
measurement obtained from the calibrator wells. The ﬁt was used to
convert the measured OD values of the samples into F-α2M con-
centrations. The calculated concentrations were multiplied by the in-
itial plasma dilution factor.
2.6.1. Freeze-thaw
Five freeze-thaw cycles were conducted of the citrate plasma pool
and the citrate plasma pool spiked with 0.5 μg/mL F-α2M (the plasma
was spiked during the ﬁrst cycle). A cycle was deﬁned as follows: The
sample was thawed in a water bath at 37 °C for 5 min following in-
cubation at RT for 15 min and ﬁnally frozen again at −80 °C for
20 min. After the ﬁve cycles, all of the samples, together with a new
ampoule of plasma, were thawed and analyzed for F-α2M as described
in Section 2.6. Each sample was analyzed twice and was measured in
duplicates.
2.6.2. Imprecision
The imprecision of the F-α2M ELISA was investigated by de-
termining the intra -and inter-assay variation of three samples with
either “low”, “medium”, or “high” OD values compared to the cali-
brator OD values. Six series were run as described in Section 2.6. On
each plate, ten replicates of the citrate plasma pool (“low”), the citrate
plasma pool spiked with 0.5 μg/mL F-α2M (“medium”) and the citrate
plasma pool spiked with 1 μg/mL F-α2M (“high”) were analyzed in
duplicate. The mean values, standard deviation, and coeﬃcient of
variation (CV) were then calculated. The intra-variation is reported as
mean CV of the intra-CV calculated for each plate. The inter-variation is
reported as the mean CV of the inter-CV between each replicate on the
six plates.
2.7. Evaluating biomaterials
The plasma compatibility of silicone, PVC, and PTFE tubings as well
as glass tubes was investigated in vitro. The diﬀerent tubings were cut in
5 cm pieces and, together with the glass tubes, warmed to 37 °C in a
pre-warmed incubator for 30 min. A 100 mM CaCl2 solution and a
24 μM TGT-lipid solution were prepared by diluting stock solutions in
TBS-buﬀer. One millilitre of the CaCl2 and TGT-lipid solutions as well as
TBS-buﬀer were heated to 37 °C for 15 min in a waterbath. After
30 min, the citrate plasma pool was thawed for 10 min at 37 °C in a
waterbath. For activation of calcium in-dependent proteases, plasma
was mixed with 1/3 pre-warmed TBS-buﬀer. 150 μL of the mixture was
immediately added to each of the diﬀerent materials and incubated for
40 min at 37 °C. Each material was investigated 10 times. The plasma
was then diluted 1:20 in PBS-TW buﬀer containing 10 mM EDTA and
200 μM PPACK and frozen at −80 °C. Subsequently, the samples were
analyzed as described in Section 2.6. The same procedure was followed
for activation of calcium dependent proteases, but plasma was instead
diluted with 1/6 part CaCl2 solution (ﬁnal concentration 16.7 mM) and
1/6 part TGT-lipid solution (ﬁnal concentration 4 μM) and incubated
for 60 min at 37 °C. Each material was investigated 10 times. The
plasma was then collected from the diﬀerent materials by centrifuga-
tion (4000 g) for 2 min, diluted 1:20 in PBS-TW buﬀer containing
10 mM EDTA and 200 μM PPACK, and frozen at−80 °C. Subsequently,
the samples were analyzed as described in Section 2.6.
3. Results
3.1. Characterization of antibody
The native PAGE (Fig. 1) demonstrated that antibody 16-11-17 re-
cognizes human F-α2M but not human N-α2M. A shift in electrophoretic
mobility, indicating increased molecular weight, was observed for F-
α2M in the presence of the antibody (lane 4) compared to F-α2M alone
(lane 3). No shift in molecular weight was observed when N-α2M was
incubated with 16–11-17 (lane 1 & 2).
The ELISA experiment demonstrated that antibody 16-11-17 re-
cognizes rRBD of α2M. Antibodies 16-11-2 and 16-11-15, on the other
hand, recognize N-α2M but not rRBD of α2M. No signal was observed
with a mouse anti-human t-PA antibody (nonsense antibody) (Table 1).
3.2. F-α2M ELISA
Spiking of plasma with 1 μg/mL F-α2M revealed a recovery per-
centage of 107% compared to the theoretical increase, whereas addi-
tion of 1.5 μg/mL F-α2M to plasma showed a recovery percentage of
106%. Parallelism was observed between serial dilutions of puriﬁed F-
α2M in buﬀer, serum, and a citrate plasma pool spiked with F-α2M. In
Fig. 2, the OD values obtained at the diﬀerent dilutions, together with
the corresponding logistic ﬁtted curves, are shown. The curves show a
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sigmoidal shape and superimpose.
The presence of PPACK in the sample dilution buﬀer had a pro-
nounced eﬀect upon F-α2M measurements in the citrate plasma pool
but not the serum pool (Table 2). In the absence of PPACK, a con-
siderably increase in F-α2M levels were observed in the citrate plasma
with increasing incubation time. The presence of PPACK, on the other
hand, resulted in equal F-α2M levels at the incubation times tested.
No eﬀect from repetitive freezing and thawing the citrate plasma
pool or the citrate plasma pool spiked with 0.5 μg/mL F-α2M, upon the
measured F-α2M concentration, was observed (Fig. 3).
For the “low” OD sample, an intra-assay CV of 3.8% and an inter-
assay CV of 5.7% were found. For the “medium” OD sample, an intra-
assay CV of 3.8% and an inter-assay CV of 6.3% were found. For the
“high” OD sample, an intra-assay CV of 3.8% and an inter-assay CV of
7.0% were found.
3.3. Biomaterial evaluation
A signiﬁcant diﬀerence in F-α2M concentrations between the con-
trol sample (time zero) and plasma samples incubated, in the absence of
calcium, in silicone, PVC, and PFTE tubings, as well as glass tubes, were
observed (p < 0.001) (Fig. 4, Left). Furthermore, while no diﬀerence
was observed between silicone, PVC, and PFTE, a 3-fold increase in F-
α2M levels was observed in plasma from glass tubes.
In the presence of calcium, F-α2M measurements increased 20–30
fold in plasma exposed to the artiﬁcial surfaces compared to the control
sample (time zero) (Fig. 4, Right). The highest increase was observed
for glass (80 fold) which also was signiﬁcantly higher than silicone,
PVC, and PFTE tubings. Silicone tubings resulted in signiﬁcantly lower
F-α2M values compared to PVC or PFTE tubings (p < 0.05). No sig-
niﬁcant diﬀerence was observed between PVC and PFTE tubings
(p > 0.05).
4. Discussion
Exposure of blood to artiﬁcial surfaces initiates a complex inter-play
involving surface related protein adsorption and cell adhesion as well as
initiation of the contact-, coagulation-, and complement systems [4]. In
clinical settings the interactions are associated with increased risk of
thrombotic and inﬂammatory manifestations [1,3]. Investigations of
the blood compatibility and development of new biomaterials currently
require a range of mono-components assays to explore contributing
factors. The ISO 10993-4 standard lists several assays for investigation
of coagulation, the complement system, and blood cell activation. A
global and sensitive marker for the blood compatibility of biomaterials
could be valuable in this regard replacing or supplementing the
Fig. 1. Electrophoretic mobility shift assay. Native PAGE analysis of native α2-macro-
globulin (N-α2M) and fast form α2-macroglobulin (F-α2M) in presence or absence of
antibody 16-11-17. Lane M: molecular weight marker. Lane 1: N-α2M, lane 2: N-α2M
+ 16-11-17, lane 3: F-α2M, lane 4: F-α2M + 16-11-17.
Table 1
Overview of antibody speciﬁcity. The interaction between the antibodies and either re-
combinant receptor-binding domain (rRBD) of α2-macroglobulin (α2M), native α2M (N-
α2M), or fast form α2M (F-α2M).
Antibody rRBD N-α2M F-α2M
16-11-17 + − +
16-11-2 − + ND
16-11-15 − + ND
Nonsense antibody − − ND
Interaction is indicated by “+”. No interaction is indicated by “−“. ND: not determined.
Fig. 2. Parallelism investigations. Parallelism between 2-fold dilution of buﬀer and ci-
trate plasma, spiked with 50 μg/mL fast form α2-macroglobulin, and serum.
Table 2
Stability of fast form α2-macroglobulin concentrations. The inﬂuence of Phe-Pro-Arg-
chloromethylketone (PPACK) in the sample dilution buﬀer upon fast form α2-macro-
globulin (F-α2M) concentrations in plasma and serum determined after incubation for 60,
120, and 180 min.
Incubation
time
(minutes)
CP (ng/mL) CP
+ PPACK
(ng/mL)
SP (ng/
mL × 10−3)
SP + PPACK
(ng/
mL × 10−3)
60 1195
(708–2060)
645
(565–727)
49.4
(46.3–52.4)
49.5
(48.3–50.8)
120 1908
(934–3043)
636
(577–657)
49.0
(47.9–50.9)
47.4
(40.3–47.7)
180 3055
(1026–4755)
666
(644–687)
49.5
(47.0–52.0)
48.8
(46.1–51.4)
The results are presented as medians and range of data obtained from four experiments.
CP: citrate plasma pool. SP: serum pool.
Fig. 3. The eﬀect of freeze-thaw cycles. The concentration of fast form α2-macroglobulin
(F-α2M) in the citrate plasma pool and the citrate plasma pool spiked with 0.5 μg/mL F-
α2M after repetitive freezing and thawing. Dark circles represent citrate plasma. Grey
rectangles represent the citrate plasma pool spiked with 0.5 μg/mL F-α2M.
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proposed assays. The broad-spectrum inhibitor α2M targets a vast
number of proteases in blood [9] including those involved in the con-
tact- and coagulation systems. In this study, we addressed whether F-
α2M could be a global and sensitive marker for activation of calcium
dependent or in-dependent proteases in plasma exposed to artiﬁcial
surfaces.
We generated a monoclonal antibody that reacts against F-α2M. By
native PAGE, we demonstrated that the antibody 16-11-17 speciﬁcally
recognized F-α2M but not N-α2M. Furthermore, we showed that 16-11-
17 recognizes rRBD of human α2M which is only exposed in F-α2M
[12–14]. Using this antibody, an ELISA measuring F-α2M was estab-
lished. We observed parallelism between serial dilutions of serum, F-
α2M in buﬀer, and citrate plasma pool spiked with F-α2M. Furthermore,
the theoretical increase in F-α2M levels of the spiked citrate plasma
pool corresponded well with the measured increase showing compar-
ability between results from diﬀerent plasmas and buﬀer.
The ELISA antigen incubation step greatly aﬀected the plasma
concentration of F-α2M which increased considerably with increasing
incubation time. Addition of the broad spectrum serine protease in-
hibitor, PPACK, to the sample dilution buﬀer was necessary to prevent
the increase in F-α2M during the incubation step. This observation
suggests that the increase in F-α2M was related to pre-analytical pro-
tease activation of the sample, presumably initiated by the high binding
ELISA plate, and indicates that F-α2M is a sensitive marker for activa-
tion of proenzymes in plasma exposed to artiﬁcial surfaces.
The F-α2M ELISA could detect protease activation in plasma in-
cubated with silicone, PVC, and PFTE tubings (plastic materials) as well
as glass tubes with or without addition of calcium. In the absence of
calcium, we observed that F-α2M concentrations were signiﬁcantly
higher in plasmas incubated with plastic materials or glass compared to
the control sample. The highest F-α2M levels were observed in plasma
incubated with glass. The proteases of the contact system are calcium
in-dependent. Furthermore, as glass is known to activate the contact
system considerably [17], these ﬁndings strongly suggest that the F-
α2M ELISA can detect activation of the contact system. The ﬁndings
that F-α2M ELISA could separate the protease activation induced by
plastic materials from that of the control sample further highlights that
F-α2M is a sensitive marker for protease activation. In previous studies,
the contribution from the contact system has been evaluated by mea-
suring formation of complexes between factor XIIa and complement C1-
esterase inhibitor [18,19]. However, in some cases, contact activation
induced by artiﬁcial surfaces could not be detected despite evidence
indicating an involvement [18]. These observations suggest that sen-
sitive assays are required to investigate contact activation induced by
biomaterials.
Exposure of plasma to plastic materials and glass, in the presence of
calcium, resulted in a massive increase in F-α2M in all samples. A 20–30
fold increase in F-α2M levels was observed from plasma samples in-
cubated in contact with plastic materials compared to the control
sample. Plasma incubated in contact with glass showed an 80 fold in-
crease in F-α2M levels compared to the control sample and a 2–4 fold
increase compared to levels measured in plasma from plastic materials.
Furthermore, the F-α2M levels in plasma incubated with silicone tub-
ings were signiﬁcantly diﬀerent from F-α2M levels in plasma from PVC
and PFTE tubings. The coagulation system is a calcium dependent and
highly potent system involving several proteases [20]. The ﬁndings
described above strongly suggest that F-α2M is a sensitive marker for
the initiation and propagation of the coagulation system. This correlates
well with the observation that the F-α2M level in the serum pool is
almost 100 times greater than that of the citrate plasma pool.
Other blood components including platelets and leukocytes are
known to be activated by medical devices [2]. Activation of neutrophils
results in the release of proteases which reportedly are regulated by
α2M [21]. Activated platelets also releases compounds including coa-
gulation factors and other proteases [22]. Although it remains to be
investigated, it is likely that F-α2M would be a marker for activation of
these blood components as well.
In conclusion, our ﬁndings demonstrate that F-α2M measurements
are useful for in vitro investigations of the plasma compatibility of
biomaterials as it is both sensitive to limited protease activation and can
detect activation of calcium dependent and in-dependent proteases. F-
a2M could, potentially, be a global and sensitive marker for the in-
vestigation of the blood compatibility of biomaterials.
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